A basic guide to particle characterization

The aim of this guide is to provide you with a basic grounding in the main particle characterization techniques currently in use within industry and academia. It assumes no prior knowledge of particle characterization theory or instrumentation and should be ideal for those new to particle characterization, or those wishing to reinforce their knowledge in the area. The guide covers introductory basics, particle characterization theory and particle characterization instrumentation, as well as a quick reference guide to help you decide which techniques might be most appropriate for your particle characterization needs.

Spotlight

DeltaHealth China

DeltaHealth is an innovative healthcare provider primarily invested by Eight Roads and its affiliate Eight Roads Ventures China. As of now, it is also the first and the only medical institution with a consultation and advisory relationship with Columbia HeartSource in China. DeltaHealth is committed to establishing an integrated network of hospitals and clinics in China that specializes in cardiovascular care and always puts patients first. We aim to bring to our patients a set of innovative and personalized medical services. To achieve this, we are building on some of the great medical management practices in the West while combining the world's excellent physicians and state-of-the-art medical technology under one roof. In addition to providing diverse and high-quality healthcare services, we also strive to improve the diagnosis and treatment of cardiovascular diseases, and deliver better experience for patients. We see this as our contribution to the development of the medical syste

OTHER WHITEPAPERS
news image

New technology advances biopharma chromatography productivity

whitePaper | February 16, 2023

Monoclonal antibody drugs (mAbs) make up more than 50 percent of the biologics on the market today, as well as a significant number of new drugs in the development pipeline. The value and impact of these therapies has been dramatic.

Read More
news image

How IPD Can Deliver for Life Sciences

whitePaper | January 1, 2020

Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.

Read More
news image

Winning with biosimilars Opportunities in global markets

whitePaper | March 14, 2022

Over the past several years, biologics have gained significant traction in the pharmaceutical industry, representing more than $150 billion in global sales in 2013. By 2020 they are predicted to generate $290 billion in revenue and comprise 27 percent of the pharmaceutical market.i

Read More
news image

How purpose-built tech can help pharmaceutical and life science companies streamline healthcare provider interactions

whitePaper | December 15, 2022

In today’s hypercompetitive pharmaceutical and life sciences (PLS) industry, strategic partnerships are more critical than ever. A smaller life sciences company may have relationships with hundreds of healthcare providers and healthcare organizations.

Read More
news image

Protein fingerprints pave the way for microarray comparison

whitePaper | June 9, 2022

Anaxomics has developed a novel method of analysis for microarray data based on the generation and subsequent comparison of 2D fingerprints for each sample. Microarray results are incorporated into a protein interaction network and embedded with all sorts of biological and medical data.

Read More
news image

Multi-channel clinical trial recruitment technology checklist

whitePaper | August 8, 2022

Biopharma R&D professionals generally admit that the current "high-cost, high-risk" development model is unsustainable. Despite technological.

Read More

Spotlight

DeltaHealth China

DeltaHealth is an innovative healthcare provider primarily invested by Eight Roads and its affiliate Eight Roads Ventures China. As of now, it is also the first and the only medical institution with a consultation and advisory relationship with Columbia HeartSource in China. DeltaHealth is committed to establishing an integrated network of hospitals and clinics in China that specializes in cardiovascular care and always puts patients first. We aim to bring to our patients a set of innovative and personalized medical services. To achieve this, we are building on some of the great medical management practices in the West while combining the world's excellent physicians and state-of-the-art medical technology under one roof. In addition to providing diverse and high-quality healthcare services, we also strive to improve the diagnosis and treatment of cardiovascular diseases, and deliver better experience for patients. We see this as our contribution to the development of the medical syste

Events